Veteran owned small business Spartan Medical Inc revealed on Wednesday that it plans to introduce Altapure LLC's AP-4 High-level Disinfection-System (HLDS) across the US market in the fight against COVID-19.
This critically needed, AP-4 advanced-ultrasonic-technology ensures that all healthcare and long-term care facilities, schools, universities, cruise lines, among others, can provide the cleanest/safest environment to fellow Americans. Altapure's first fully integrated high-level disinfection system AP–4 Medical HLD System will eliminate all bacteria, spores and viruses in a treated space. The system is easily operated by one person and many facilities have one person running two to three machines at a time.
The AP–4 is a single mobile unit platform, containing a combined submicron aerosol output device and environmental air re-processor system with data feedback. The process's agent is organic, biodegradable, food safe and leaves zero residue. Its PAA agent is an EPA registered cold sterilant, bactericide, fungicide, virucide and sporicide. In short, there has not yet been a pathogen that can survive the disinfection cycle, making the implementation of this state-of-the-art solution paramount during COVID-19 and beyond.
In collaboration with NASA, Altapure has shown efficacy in the sterilization of PPE with the 'peracetic acid technology.
BioCryst wins FDA approval for oral HAE prophylaxis in young children
ALR Technologies announces GluCurve Pet CGM relaunch in Canada
Galderma secures EU MDR certification for Sculptra, expanding use to multiple body areas
Clinical Laserthermia Systems applies for CE marking of ClearPoint Prism neuro laser system
Bonesupport shifts CERAMENT V review to FDA's De Novo pathway
Neola Medical secures US patent for disposable lung monitoring probes
Remington Medical's VascuChek 2.0 Cordless Bluetooth-Enabled Doppler Secures FDA Clearance
Aetna to launch generative AI-powered conversational experience
Maxx Orthopedics Receives FDA 510(k) Clearance for Its Libertas® Bipolar Hip System
Ascletis Pharma announces ASC36 and ASC35 co-formulation for clinical development
Adocia files patent for long-acting peptide platform AdoXLong and updates on BioChaperone studies
Nurami Medical completes Phase 1 milestones in EIC-backed grant for Artifix
Organon to sell JADA System to Laborie for up to USD465m
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities